INVO Bioscience Stock (NASDAQ:INVO)

Revenue Ownership Financials Chart

Previous Close

$0.85

52W Range

$0.63 - $3.50

50D Avg

$0.77

200D Avg

$0.90

Market Cap

$3.25M

Avg Vol (3M)

$1.15M

Beta

1.44

Div Yield

-

INVO Company Profile

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

25

IPO Date

Nov 02, 2020

Website

INVO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 22	Dec 21	Dec 20
Clinic Revenue	$614.85K	$43.74K	-
Product Revenue	-	$544.94K	-
License Revenue	-	$3.57M	-
DomesticLicensingDistributionFeeMember	-	-	$714.29K
DomesticPhysiciansMember	-	-	$323.00K

Fiscal year ends in Dec 23 | Currency in USD

INVO Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$3.02M	$822.20K	$4.16M
Operating Income	$-6.77M	$-10.63M	$-5.22M
Net Income	$-8.03M	$-10.89M	$-6.65M
EBITDA	$-8.73M	$-10.83M	$-5.37M
Basic EPS	$-5.13	$-17.97	$-12.52
Diluted EPS	$-5.13	$-17.97	$-12.52

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 23Aug 14, 23 | 10:50 PM

Q1 23May 15, 23 | 8:05 PM

Q4 22Apr 17, 23 | 7:01 PM

Peer Comparison

Ticker	Company
NLSP	NLS Pharmaceutics AG
CLPS	CLPS Incorporation
LIXT	Lixte Biotechnology Holdings, Inc.
ENTX	Entera Bio Ltd.
ENVB	Enveric Biosciences, Inc.